Prevention of hepatocellular carcinoma

Clinics in Liver Disease

Volumn 9, Issue 2, 2005, Pages 329-346

  Craxì, Antonio ^a   Cammà, Calogero ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; LAMIVUDINE; POLYPRENOIC ACID; RETINOID;

ADOPTIVE IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; GEOGRAPHIC DISTRIBUTION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; MOLECULAR MODEL; PREDICTION; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; VACCINATION;

EID: 17044427118     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.12.008     Document Type: Conference Paper

References (74)

1. D.M. Parkin, F. Bray, and J. Ferlay Estimating the world cancer burden: GLOBOCAN 2000 Int J Cancer 94 2001 153 156
2. Y. Tanaka, K. Hanada, and M. Mizokami Inaugural Article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades Proc Natl Acad Sci USA 99 2002 15584 15589
3. M.F. Yuen, C.C. Cheng, and I.J. Lauder Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience Hepatology 31 2000 330 335
4. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
5. S.M. Lippman, and W.K. Hong Cancer prevention by delay. Commentary re: J.A. O'Shaughnessy et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development Clin Cancer Res 8 2002 305 313
6. T. Stroffolini, E. Sagnelli, P. Almasio Italian Hospitals Collaborating Groups Characteristics of liver cirrhosis in Italy: results from a multicenter national study Dig Liver Dis 36 2004 56 60
7. M.B. Sporn, N.M. Dunlop, and D.L. Newton Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Fed Proc 35 1976 1332 1338 [review]
8. H. Tsukuma, T. Hiyama, and S. Tanaka Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 24 328 1993 1797 1801
9. R.G. Simonetti, C. Camma, and F. Fiorello Hepatocellular carcinoma. A worldwide problem and the major risk factors Dig Dis Sci 36 1991 962 972 [review]
10. H.B. El-Serang, and A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
11. F. Donato, P. Boffetta, and M. Puoti A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma Int J Cancer 75 3 1998 347 354
12. M. Manno, C. Cammà, and F. Schepis Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years Gastroenterology 127 2004 756 763
13. M. Torbenson, and D.L. Thomas Occult hepatitis B Lancet Infect Dis 2 2002 479 486
14. I. Cacciola, T. Pollicino, and G. Squadrito Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease N Engl J Med 341 1999 22 26
15. T. Pollicino, G. Squadrito, and G. Cerenzia Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection Gastroenterology 126 2004 102 110
16. R.G. Simonetti, C. Camma, and F. Fiorello Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study Ann Intern Med 116 1992 97 102
17. J.W. Grisham Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma W.B. Coleman G.J. Tsongalis The molecular basis of human cancer 2001 Humana Press Totowa (NJ) 269 346
18. J.H. Kao, and D.S. Chen Global control of hepatitis B virus infection Lancet Infect Dis 2 2002 395 403
19. M. Kew, G. Francois, D. Lavanchy Viral Hepatitis Prevention Board Prevention of hepatitis C virus infection J Viral Hepat 11 2004 198 205 [review]
20. R.E. Omer, A. Kuijsten, and A.M. Kadaru Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma Nutr Cancer 48 2004 15 21
21. S. Nishiguchi, T. Kuroki, and S. Nakatani Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
22. G. Mazzella, E. Accogli, and S. Sottili Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis J Hepatol 24 1996 141 147
23. S. Bruno, E. Silini, and A. Crosignani Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study Hepatology 25 1997 754 758
24. G. Fattovich, G. Giustina, and F. Degos Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
25. International Interferon-alpha Hepatocellular Carcinoma Study Group Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study Lancet 351 1998 1535 1539
26. Y. Imai, S. Kawata, S. Tamura for the Osaka Hepatocellular Carcinoma Prevention Study Group Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 1998 94 99
27. A. Gramenzi, P. Andreone, and S. Fiorino Impact of interferon therapy on the natural history of HCV-related cirrhosis Gut 48 2001 843 848
28. L. Serfaty, H. Aumaître, and O Cazouillères Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
29. S. Sofia, A. Casali, and E. Buscarini Effect of lymphoblastoid IFN in the treatment of liver cirrhosis and prevention of HCC Ital J Gastroenterol Hepatol 30 1998 A31
30. L. Benvegnù, L. Chemello, and F. Noventa Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis Cancer 83 1998 901 909
31. A. Shioda, M. Moriyama, and M. Kaneko Long-term prognosis of hepatocellular carcinoma developing after treatment of interferon in patients with chronic hepatitis C and liver cirrhosis Hepatology 30 1999 268A
32. H. Yoshida, Y. Shiratori, M. Moriyama for the IHIT Study Group Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chornic hepatitis C in Japan Ann Intern Med 131 1999 174 181
33. D. Mura, R. Deliperi, and L. Fastame Five year follow-up after Interferon therapy in HCV-positive compensated cirrhosis Ital J Gastroenterol Hepatol 30 1998 A114
34. D.-C. Valla, M. Chevallier, and P. Marcellin Treatment of hepatitis C virus-related cirrhosis: a randomized controlled trial of interferon alfa 2b versus no treatment Hepatology 29 1999 1870 1875
35. C.J. Oon Long-term survival following treatment of hepatocellular carcinoma in Singapore Cancer Chemother Pharmacol 31 Suppl 1992 S137 S142
36. G. Fattovich, G. Giustina, G. Realdi and the European Concerted Action on Viral Hepatitis (EUROHEP) Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa Hepatology 26 1997 1338 1342
37. V. Di Marco, O. Lo Iacono, and C. Cammà The long term course of chronic hepatitis B Hepatology 30 1999 257 264
38. K. Ikeda, S. Saitoh, and Y. Suzuki Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus Cancer 82 1998 827 835
39. A. Kasahara, N. Hayashi, and K. Mochizuki Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C Hepatology 27 1998 1394 1402
40. C. Cammà, V. Di Marco, and O. Lo Iacono Long-term course of interferon-treated chornic hepatitis C J Hepatol 28 1998 531 537
41. I. Miyajima, M. Sata, and R. Kumashiro The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment Oncol Rep 5 1998 201 204
42. C. Cammà, M. Giunta, and P. Andreone Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach J Hepatol 34 2001 593 602
43. G. Fattovich, G. Giustina, and G. Realdi Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology 26 1997 1338 1342
44. P. Almasio, C. Cammà, and M. Giunta Treatment of chronic hepatitis B: an evidence-based review J.W.D. McDonald A. Burroughs B.G. Feagan Evidence-based gastroenterology and hepatology 1999 BMJ Publications London 305 321
45. A. Craxì, D. Di Bona, and C. Camma Interferon-alpha for HBeAg-positive chronic hepatitis B J Hepatol 39 2003 S99 S105 [review]
46. G.V. Papatheodoridis, E. Manesis, and S.J. Hadziyannis The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 2001 306 313
47. S.M. Lin, I.S. Sheen, and R.N. Chien Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 1999 971 975
48. M.F. Yuen, C.K. Hui, and C.C. Cheng Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 2001 139 145
49. C. Niederau, T. Heintges, and S. Lange Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1996 1422 1427
50. V. Di Marco, O. Lo Iacono, and C. Camma The long-term course of chronic hepatitis B Hepatology 30 1999 257 264
51. D.K. Chen, C. Yim, and K. O'Rourke Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population J Hepatol 30 1999 557 563
52. A.A. Evans, M. Fine, and W.T. London Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy J Infect Dis 176 1997 845 850
53. J. Korenman, B. Baker, and J. Waggoner Long-term remission of chronic hepatitis B after alpha-interferon therapy Ann Intern Med 114 1991 629 634
54. A.S. Lok, H.T. Chung, and V.W. Liu Long-term follow-up of chronic hepatitis B patients treated with interferon alfa Gastroenterology 105 1993 1833 1838
55. D.T. Lau, J. Everhart, and D.E. Kleiner Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa Gastroenterology 113 1997 1660 1667
56. G. Fattovich, G. Giustina, and E. Christensen Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) Gut 46 2000 420 426
57. Y.S. Hsu, R.N. Chien, and C.T. Yeh Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
58. R. Esteban Management of chronic hepatitis B: an overview Semin Liver Dis 22 2002 1 6
59. Y.F. Liaw, J.J.Y. Sung, and W.C. Chow Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial Hepatology 38 2003 262A
60. V. Di Marco, P. Marzano, and P. Lampertico Virological and clinical events during lamivudine therapy for anti-HBE/HBV-DNA positive chronic liver disease Hepatology 40 2004 883 891
61. C. Cammà, V. Di Marco, and A. Orlando Treatment of small hepatocellular carcinoma with radio-frequency thermal ablation (rfta): a prognostic model Dig Liver Dis 36 2004 26A
62. A. Orlando, A. D'Antoni, and C. Camma Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model Am J Gastroenterol 95 2000 2921 2927
63. R.A. Lencioni, H.P. Allgaier, and D. Cioni Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection Radiology 228 2003 235 240
64. C. Cammà, F. Schepis, and A. Orlando Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 2002 47 54
65. Y. Muto, H. Moriwaki, and M. Ninomiya Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid,in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group N Engl J Med 334 1996 1561 1567
66. W.Y. Lau, T.W. Leung, and S.K. Ho Adjuvant intra-arterial iodine-131-labelled lipiodol for resectablehepatocellular carcinoma: a prospective randomised trial Lancet 353 1999 797 801
67. T. Takayama, T. Sekine, and M. Makuuchi Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellularcarcinoma: a randomised trial Lancet 356 2000 802 807
68. K. Ikeda, Y. Arase, and S. Saitoh Interferon beta prevents recurrence of hepatocellular carcinoma after completeresection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer Hepatology 32 2000 228 232
69. S. Kubo, S. Nishiguchi, and K. Hirohashi Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy Br J Surg 89 2002 418 422
70. T. Suou, A. Mitsuda, and M. Koda Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study Hepatol Res 20 2001 301 311
71. S. Miyaguchi, T. Watanabe, and H. Takahashi Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels Hepatogastroenterology 49 2002 724 729
72. Y. Shiratori, S. Shiina, and T. Teratani Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus Ann Intern Med 138 2003 299 306
73. M. Okuno, S. Kojima, and R. Matsushima-Nishiwaki Retinoids in cancer chemoprevention Curr Cancer Drug Targets 4 2004 285 298
74. S. Kojima, M. Okuno, and R. Matsushima-Nishiwaki Acyclic retinoid in the chemoprevention of hepatocellular carcinoma Int J Oncol 24 2004 797 805